Lilly Asia Ventures and Sinopharm Healthcare Fund co-led the round that will fund a phase 3 trial for Ansun Biopharma's parainfluenza treatment.

Johnson & Johnson, Vactech and MacroGenics all own stakes in Provention they got through licensing drug candidates to the company.

Beam, a genetic medicine developer in which Editas Medicine is a shareholder, has emerged from stealth with an $87m series A round.

NUS spinout MediSix has obtained $20m from investors including Osage University Partners to commercialise research into leukaemia and lymphoma treatments.

Beam has emerged out of Harvard University with $87m in series A funding to commercialise gene editing technology, with additional research licensed from Broad Institute and Editas Medicine.

The endoscope developer has raised a major part of a $15m round, the tranche being led by Hoya Corporation.

The capital will help turn early-stage university ideas into successful spinouts, having already backed a Car T-based immuno-oncological therapy for multiple myeloma.

The Alphabet, Celgene and Mayo Clinic-backed gut-body drug developer floated at the top of its range, after about $167m in VC funding.

The China-based liver disease treatment developer, whose backers include Tasly Pharmaceuticals, will float in Hong Kong following rule changes.